. 2021 Jan 4;114(1):51–56. doi: 10.14423/SMJ.0000000000001200
Copyright © 2021 by The Southern Medical Association
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
Table 2.
Potential benefits of RAAS inhibitors in COVID-19
